Daniel Mimouni
Overview
Explore the profile of Daniel Mimouni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
1052
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Engler Markowitz M, Barak Levitt J, Merose R, Didkovski E, Snast I, Oren-Shabtai M, et al.
Clin Exp Dermatol
. 2025 Mar;
PMID: 40083321
Background: Vitiligo-like leukoderma is being increasingly reported in patients with breast cancer treated with cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors. Objective: The aim of the study was to systematically...
2.
Lyakhovitsky K, Damiani G, Mimouni D, Aronovich A
Arch Dermatol Res
. 2024 Sep;
316(8):611.
PMID: 39259320
The association between systemic scleroderma and malignancy is well-documented, but there is limited data on the relationship between morphea and malignancy. This study aims to assess the incidence and types...
3.
Hilewitz D, Trattner A, Noyman Y, Mimouni D, Snast I
Contact Dermatitis
. 2024 Jun;
91(3):222-227.
PMID: 38923529
Background: Tefillin are a religious article worn by Jewish men during daily prayer. Tefillin dermatitis secondary to potassium dichromate sensitivity is recognised, but data remain sparse. Objective: To investigate the...
4.
Barak Levitt J, Barmatz S, Fisch-Gilad S, Taieb Y, Dalal A, Afshari K, et al.
Isr Med Assoc J
. 2024 May;
26(5):283-288.
PMID: 38736342
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease involving apocrine gland-bearing regions. There is an under-representation of non-Caucasians in epidemiologic studies of HS. The characteristics of HS in...
5.
Oren-Shabtai M, Mimouni D, Nosrati A, Atzmony L, Kaplan B, Barzilai A, et al.
Front Immunol
. 2023 May;
14:1157250.
PMID: 37180101
Background: Bullous pemphigoid (BP) is the most common autoimmune subepidermal bullous disease. Topical or systemic corticosteroids are often used as the first-line treatment. However, long-term corticosteroid use may lead to...
6.
Guignant M, Tedbirt B, Murrell D, Amagai M, Aoki V, Bauer J, et al.
JID Innov
. 2022 Jul;
2(4):100129.
PMID: 35860447
Many treatments are currently proposed for treating patients with bullous pemphigoid (BP). We assessed treatment modalities of BP depending on the different countries, BP extent, and patients' comorbidities. We surveyed...
7.
Oren-Shabtai M, Sloutsky N, Lapidoth M, Mimouni D, Chorny I, Snast I, et al.
Lasers Med Sci
. 2022 Apr;
37(7):2899-2905.
PMID: 35412157
Actinic keratoses are common cutaneous lesions with a potential to progress to invasive squamous cell carcinoma. Therefore, treatment is crucial. The Tixel® is a noninvasive thermomechanical device designed to transfer...
8.
Amitay-Laish I, Solomon-Cohen E, Feuerman H, Didkovsky E, Davidovici B, Leshem Y, et al.
Int J Dermatol
. 2022 Apr;
61(10):1245-1252.
PMID: 35398883
Background: Data on Demodex in the immunosuppressed state is limited, focusing mainly on patients with human immunodeficiency virus and hematological malignancies. The aim of this study was to describe the...
9.
Akerman L, Mimouni D, Nosrati A, Hilewitz D, Solomon-Cohen E
J Clin Aesthet Dermatol
. 2022 Mar;
15(3):53-56.
PMID: 35342506
Background: Postacne facial scars are often associated with significant patient distress. Energy-based devices, including non-ablative lasers, are commonly used for the treatment of postacne scarring. There is relatively limited data...
10.
Nosrati A, Mimouni T, Hodak E, Gdalevich M, Oren-Shabtai M, Levi A, et al.
Dermatol Ther
. 2022 Feb;
35(5):e15397.
PMID: 35194896
Rituximab is the front-line therapy for pemphigus disease. Although very effective, relapse rates are high. We assessed factors associated with disease remission and early relapse following the first rituximab cycle....